A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain
Open Access
- 1 April 2003
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 14 (4) , 656-657
- https://doi.org/10.1093/annonc/mdg153
Abstract
ZD1839 (Iressa) is a synthetic, oral anilinoquinazoline with submicromolar specificity for the epidermal growth factor receptor (EGFR). In non-small-cell lung cancer (NSCLC), ZD1839 has shown significant antitumor activity, even in heavily pretreated patients. We present a patient with NSCLC who has brain metastases and was enrolled in hospice care prior to therapy with ZD1839, which produced a sustained clinical response.Keywords
This publication has 4 references indexed in Scilit:
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer.Clinical Lung Cancer, 2002
- Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2001
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000